Rosalind Advisors Inc. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-13 1:41 pm Purchase | 2025-02-13 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 1,062,500 1.200% | 312,500 (+41.67%) | Filing |
| 2024-10-23 2:44 pm Sale | 2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 750,000 1.030% | -641,577 (-46.10%) | Filing |
| 2024-07-11 5:52 pm Purchase | 2024-06-28 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 1,391,577 1.980% | 465,561 (+50.28%) | Filing |
| 2024-04-25 7:39 pm Sale | 2024-03-31 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 926,016 1.340% | -1,573,977 (-62.96%) | Filing |
| 2023-02-15 1:16 pm Purchase | 2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 2,499,993 4.200% | 314,329 (+14.38%) | Filing |
| 2022-03-09 5:09 pm Purchase | 2022-02-28 | 13G | Trevi Therapeutics, Inc. TRVI | Rosalind Advisors Inc. | 2,185,664 8.500% | 2,185,664 (New Position) | Filing |